June 2006 INOtherapy manufactured by INO Therapeutics Inc.
The mandate of the Patented Medicine Prices Review Board (PMPRB) is two-fold:
Regulatory To protect consumer interests and contribute to Canadian health care by ensuring that prices charged by manufacturers for all patented medicines sold in Canada, under prescription or over the counter, are not excessive.
Reporting To contribute to informed decisions and policy making by reporting on pharmaceutical trends and on the R&D spending by pharmaceutical patentees.
The PMPRB is a quasi-judicial tribunal that carries out its mandate independently of other bodies such as Health Canada, which approves drugs for safety and efficacy, and public drug plans, which approve the listing of drugs on their respective formularies for reimbursement purposes.
It is mandated to review the prices being charged by manufacturers of patented drugs for compliance with the Patent Act. If, following a public hearing, the Board finds that a price is excessive it may order a reduction in the price to a non-excessive level and the offset of excessive reveues.
Price Review ProcessIn accordance with the Patent Act, the Board has established excessive price guidelines in consultation with provincial ministers of health, consumer groups, the pharmaceutical industry and other stakeholders. The determination of whether a price is “excessive” is based on the factors listed in the Patent Act, which include prices of other drugs within the therapeutic class and prices at which the drug is sold in other countries.
The general effect of the Guidelines is to limit the prices of most new patented drugs to the highest price of comparable drugs on the Canadian market that treat the same condition or disease; in the case of a breakthrough drug, that provides substantial improvement over existing available therapies. the price in Canada may not exceed the median of the prices for the same drug in seven other industrialized countries specified in the Patented Medicines Regulations, 1994 (Règlement).
The PMPRB also reviews any subsequent price increases, to ensure that prices of patented medicines are, at no time, excessive. The PMPRB reviews the price of every patented medicine for the duration of any patent that pertains to the medicine.
INOtherapyThe price of INOtherapy has been under the Board´s jurisdiction since September 2004, when it was first sold under Health Canada´s Special Access Program (SAP).
Indication
Drug approval (Health Canada)
Patent issuance (Canadian Intellectual Property Office; Industry Canada)
Price Review
2006-06-15 Patented Medicine Prices Review Board Resource: Sylvie Dupont, Secretary of the Board (613) 954-8299; sdupont@pmprb-cepmb.gc.ca